NCT06328036 2024-12-30
Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
National Cancer Institute (NCI)
Stanford University
McGill University Health Centre/Research Institute of the McGill University Health Centre
Barretos Cancer Hospital